Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint - Fierce Biotech
AI Summary1 min read
TL;DR
Grail's stock plummeted after its NHS-Galleri cancer blood test trial failed to meet its primary endpoint, raising doubts about the test's effectiveness and prospects.
Tags
Grailcancer blood testNHS trialstock crashclinical trial failure
- Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint Fierce Biotech
- A Cancer Detection Test Fails in Major Study The New York Times
- Grail shares plummet after cancer test falls short in three-year NHS study firstwordpharma.com
- Multi-cancer blood test missed key goal in NHS trial BBC
- Grail shares plummet after UK study raises doubts over cancer test's prospects Reuters